Trastuzumab and Biosimilars (VA-25-00052526)   2

Background
The Department of Veterans Affairs (VA) is issuing this solicitation to establish a supply source for Trastuzumab and Biosimilars through the VA and Department of Defense (DoD) Pharmaceutical Prime Vendor (PPV) Programs. The goal is to ensure availability and consistency of these pharmaceutical products for nationwide usage while obtaining volume-based pricing. This contract will support various government participants, including VA facilities, DoD, Indian Health Service (IHS), and Bureau of Prisons (BOP).

Work Details
The contract includes the supply of Trastuzumab in two formulations: 150mg and 420mg vials. The quantities required are as follows:

1. **Trastuzumab 150mg/Vial Injection and Biosimilars**
- Base Year: 10,297 vials
- Option Year One: 10,297 vials
- Option Year Two: 10,297 vials
- Option Year Three: 10,297 vials
- Option Year Four: 10,297 vials

2. **Trastuzumab 420mg/Vial Injection and Biosimilars**
- Base Year: 1,426 vials
- Option Year One: 1,426 vials
- Option Year Two: 1,426 vials
- Option Year Three: 1,426 vials
- Option Year Four: 1,426 vials.

Offerors must provide an 11-digit National Drug Code (NDC) number unique to their company for each drug offered. The prices must include a Cost Recovery Fee of 0.5%.

Place of Performance
Products will be delivered to various locations under the VA PPV Program across the United States.